Transcription dosage compensation does not occur in Down syndrome

Background: Trisomy 21, also known as Down syndrome, describes the genetic condition of having an extra copy of chromosome 21. The increase in DNA copy number has led to the "DNA dosage hypothesis", which claims that the level of gene transcription is proportional to the gene’s DNA copy number. Yet many reports have suggested that a proportion of chromosome 21 genes are dosage compensated back towards typical expression levels (1.0x). In contrast, other reports suggest that dosage compensation is not a common mechanism of gene regulation in Trisomy 21, providing support to the DNA dosage hypothesis. Results In our work, we use both simulated and real data to dissect the elements of differential expression analysis that can lead to the appearance of dosage compensation even when compensation is demonstrably absent. Using lymphoblastoid cell lines derived from a family of an individual with Down syndrome, we demonstrate that dosage compensation is nearly absent at both nascent transcription (GRO-seq) and steady-state RNA (RNA-seq) levels. Conclusions Transcriptional dosage compensation does not occur in Down syndrome. Simulated data containing no dosage compensation can appear to have dosage compensation when analyzed via standard methods. Moreover, some chromosome 21 genes that appear to be dosage compensated are consistent with allele specific expression.

[1]  L. Malle,et al.  Down syndrome and type I interferon: not so simple. , 2021, Current opinion in immunology.

[2]  Jason M. Sheltzer,et al.  Extensive protein dosage compensation in aneuploid human cancers , 2021, bioRxiv.

[3]  Jacob T. Stanley,et al.  Protocol variations in run-on transcription dataset preparation produce detectable signatures in sequencing libraries , 2021, BMC Genomics.

[4]  L. Vitale,et al.  The transcriptome profile of human trisomy 21 blood cells , 2021, Human Genomics.

[5]  Noah Dephoure,et al.  Consequences of aneuploidy in human fibroblasts with trisomy 21 , 2020, Proceedings of the National Academy of Sciences.

[6]  Michelle S. Scott,et al.  Handling multi-mapped reads in RNA-seq , 2020, Computational and structural biotechnology journal.

[7]  Dhruba Kumar Bhattacharyya,et al.  Differential Expression Analysis of RNA-seq Reads: Overview, Taxonomy, and Tools , 2020, IEEE/ACM Transactions on Computational Biology and Bioinformatics.

[8]  D. Cimini,et al.  Aneuploidy and gene expression: is there dosage compensation? , 2019, Epigenomics.

[9]  Rani K. Powers,et al.  Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors , 2019, Nature Communications.

[10]  Christopher D. Brown,et al.  The GTEx Consortium atlas of genetic regulatory effects across human tissues , 2019, Science.

[11]  S. Antonarakis,et al.  Single cell transcriptome in aneuploidies reveals mechanisms of gene dosage imbalance , 2019, Nature Communications.

[12]  J. Hadfield,et al.  RNA sequencing: the teenage years , 2019, Nature Reviews Genetics.

[13]  L. Vitale,et al.  Integrated Quantitative Transcriptome Maps of Human Trisomy 21 Tissues and Cells , 2018, Front. Genet..

[14]  A. Reymond,et al.  Slightly deleterious genomic variants and transcriptome perturbations in Down syndrome embryonic selection , 2018, Genome research.

[15]  Evan G. Williams,et al.  Systematic proteome and proteostasis profiling in human Trisomy 21 fibroblast cells , 2017, Nature Communications.

[16]  S. Fernandez,et al.  Power analysis for RNA-Seq differential expression studies , 2017, BMC Bioinformatics.

[17]  Stephane E. Castel,et al.  Quantifying the regulatory effect size of cis-acting genetic variation using allelic fold change , 2016, bioRxiv.

[18]  Peng Liu,et al.  Sample size calculation while controlling false discovery rate for differential expression analysis with RNA-sequencing experiments , 2016, BMC Bioinformatics.

[19]  Michael Springer,et al.  No current evidence for widespread dosage compensation in S. cerevisiae , 2016, eLife.

[20]  N. Brockdorff,et al.  Dosage compensation in mammals. , 2015, Cold Spring Harbor perspectives in biology.

[21]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[22]  Pedro G. Ferreira,et al.  Transcriptome and genome sequencing uncovers functional variation in humans , 2013, Nature.

[23]  E. Dermitzakis,et al.  Expression quantitative trait loci: present and future , 2013, Philosophical Transactions of the Royal Society B: Biological Sciences.

[24]  Ellen T. Gelfand,et al.  The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.

[25]  A. Amon,et al.  New insights into the troubles of aneuploidy. , 2012, Annual review of cell and developmental biology.

[26]  John T. Lis,et al.  Transcription Regulation Through Promoter-Proximal Pausing of RNA Polymerase II , 2008, Science.

[27]  M. Delorenzi,et al.  Natural gene-expression variation in Down syndrome modulates the outcome of gene-dosage imbalance. , 2007, American journal of human genetics.

[28]  B. Oliver,et al.  Dosage compensation goes global. , 2007, Current opinion in genetics & development.

[29]  John D. Storey,et al.  Gene-expression variation within and among human populations. , 2007, American journal of human genetics.

[30]  Ingo Ruczinski,et al.  Primary and secondary transcriptional effects in the developing human Down syndrome brain and heart , 2005, Genome Biology.

[31]  P. Hunt,et al.  To err (meiotically) is human: the genesis of human aneuploidy , 2001, Nature Reviews Genetics.

[32]  Kazuhiro Ishii,et al.  [Down syndrome]. , 2003, Ryoikibetsu shokogun shirizu.

[33]  Elizabeth M. Smigielski,et al.  dbSNP: the NCBI database of genetic variation , 2001, Nucleic Acids Res..